http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-508280-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb75b0b19820e3833ebdcb31603b242b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-52
filingDate 1999-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_195755e705095b49c6038d68e9492cf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b29cd9b9d465292cb24b8df43075896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_259b52d5bb431a4a96959ce51adecda7
publicationDate 2002-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-508280-A
titleOfInvention 2- or 3-cyanoiminoquinoxaline derivatives useful as glutamate receptor antagonists
abstract A cyanoiminoquinoxaline derivative of the formula (II) is disclosed, wherein: X and Y are each independently O or NCN, provided that at least one of X and Y is NCN; R1, R2, R3, and R4 are each independently hydrogen, halogen, nitro, optionally substituted heterocyclic group etc.; R5 is hydrogen hydroxy, optionally substituted lower alkyl; R1 and R2, R2 and R3, R3 and R4, and R4 and R5, each taken together with the adjacent atoms may form a carbocycle which may be substituted or may contain a heteroatom(s). Such compounds are useful as preventive or therapeutic agents for diseases due to hyperexcitation of glutamate receptors, including stroke, cerebral infarction.
priorityDate 1998-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID153896052
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458427722
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID429402198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410516039
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18629186

Total number of triples: 34.